Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Dasatinib vs imatinib in the treatment of paediatric ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.12.19
Views: 237
Rating:

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dr Shuhong Shen speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study treating paediatric Acute Lymphoblastic Leukaemia.

This open-label phase III randomised study was conducted at 20 hospitals in China. Of the 225 patients with the diagnosis, 35 declined and 1 died before treatment.

Intensive chemotherapy including dasatinib at 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared to imatinib at 300 mg/m2 per day and provided excellent control of central-nervous-system leukaemia without the use of prophylactic cranial irradiation.
 

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation